anti-NKG2D CAR NK-cell therapy (Xinxiang Medical University)

N/A

Report date: 2025/03/18 20:00:05

Base Information

Drug Nameanti-NKG2D CAR NK-cell therapy (Xinxiang Medical University)
Drug Alias NameNKG2D-CAR-NK92 cell therapy (Xinxiang Medical University)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionNKG2-D type II integral membrane protein modulators
TargetsNKG2-D type II integral membrane protein
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesXinxiang Medical University
China Registration ClassN/A

Develop Information

Active CompaniesXinxiang Medical University
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A